This report provides a comprehensive overview of the progress made by India in terms of establishment and functionality of Special Newborn Care Units (SNCUs) during the two year period from April 2013 to March 2015. It describes the progress in the operational status (numbers, bed strength, human re...source availability), the profile of babies admitted in these units and of those babies who died during stay. In addition it provides individual state specific statistics to facilitate differential planning and better monitoring of these units in India.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
ts goals are to ensure that:
Children and parents experience fewer conflicts;
Parents make better decisions about the care of their children and are better able to solve problems; and
Children feel more supported by their families to further their education and make good decisions a...nd healthy life choices.
This discussion guide is intended to facilitate discussion and peer learning, during which participants can learn from each other’s experiences and support each other. It is designed for group session discussions, as well as for one-on-one guidance in the home. It should be used with the "Better Parenting Nigeria" Facilitator’s Manual
more
Somali version of How to use a Partograph
Jaantuska fooshu waa aalad muhiim ah marka lala kala wareegayo macluumaad labada xilli ee shaqada. Wuxuu kuu samaynayaa sawir kaas oo u muujinaya dhaqtarka in bukaankan aanu ladnayn una baahan tahay doc wareen.
Filimkan waxaynu ku sharixi doonaa goorta... iyo sida loo isticmaalo Jaantuska Foosha iyo sida uu uga jawaabo macluumaadka la galiyo.
Translation thanks to Aidarus Khalif and Fouzia Ismail and Adbirahman Dahir Aden at the Somaliland Nursing and Midwifery Association (SLNMA).
http://medicalaidfilms.org/our-films/somali-films/?v=80072696
more
This fact sheet is based on a systematic review of the literature on HPV and cervical cancer epidemiology, and a survey on policies and practices related to the prevention and control of cervical cancer among women living with HIV (WLHIV) to PAHO Member States. It details scorecards on the advances ...of countries against WHO recommendations and international commitments for cervical cancer prevention and control among WLHIV.
more
Achieving universal access to WASH in health care facilities requires political will and strong leadership at both national and facility levels, but is highly cost-effective, and would yield substantial health benefits. A global analysis estimated that universal basic WASH services in health care f...acilities could be achieved in 46 least developed countries (LDCs) by 2030 for less than US$10 billion, which represents additional expenditures of less than US$1 per person per year.
more
Kenya is home to 4 million girls and women who have experienced FGM. Overall, 21 per cent of girls and women aged 15 to 49 years have undergone the practice, varying from 98 per cent in the North Eastern region to 1 per cent in the Western region
Almost 50 million girls and women have undergone FGM in five countries in the Middle East and North Africa, accounting for one quarter of the global total
This film is the Bemba version of our English film: Cervical cancer - Understanding prevention screening and treatment.